Sei Investments Co. Has $4.08 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Sei Investments Co. trimmed its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 0.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 48,230 shares of the company’s stock after selling 131 shares during the period. Sei Investments Co. owned about 0.10% of Axsome Therapeutics worth $4,081,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Assetmark Inc. bought a new position in Axsome Therapeutics during the fourth quarter worth about $52,000. R Squared Ltd acquired a new stake in shares of Axsome Therapeutics in the fourth quarter valued at approximately $64,000. KBC Group NV boosted its stake in shares of Axsome Therapeutics by 40.5% in the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after buying an additional 385 shares during the period. Xponance Inc. grew its position in Axsome Therapeutics by 11.6% during the fourth quarter. Xponance Inc. now owns 2,659 shares of the company’s stock worth $225,000 after buying an additional 277 shares in the last quarter. Finally, Corient Private Wealth LLC acquired a new position in Axsome Therapeutics during the fourth quarter valued at approximately $239,000. Institutional investors own 81.49% of the company’s stock.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 22.40% of the stock is owned by company insiders.

Axsome Therapeutics Price Performance

Shares of NASDAQ AXSM opened at $109.75 on Thursday. The company has a market capitalization of $5.35 billion, a PE ratio of -18.32 and a beta of 0.88. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The stock’s 50 day moving average price is $120.62 and its 200-day moving average price is $101.58. Axsome Therapeutics, Inc. has a twelve month low of $64.11 and a twelve month high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The business had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million. On average, equities analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on AXSM. Cantor Fitzgerald reissued an “overweight” rating and set a $153.00 price target on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. Mizuho boosted their price objective on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the stock an “outperform” rating in a research note on Thursday, March 27th. William Blair reissued an “outperform” rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. Truist Financial boosted their target price on Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Finally, Leerink Partners increased their price target on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday, February 10th. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $167.64.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.